368 related articles for article (PubMed ID: 37058306)
1. Estimated Costs and Outcomes Associated With Use and Nonuse of Medications for Opioid Use Disorder During Incarceration and at Release in Massachusetts.
Chatterjee A; Weitz M; Savinkina A; Macmadu A; Madushani RWMA; Potee RA; Ryan D; Murphy SM; Walley AY; Linas BP
JAMA Netw Open; 2023 Apr; 6(4):e237036. PubMed ID: 37058306
[TBL] [Abstract][Full Text] [Related]
2. Expanding access to Medication for Opioid Use Disorder (MOUD) in jails: A comprehensive program evaluation.
Pourtaher E; Gelberg KH; Fallico M; Ellendon N; Li S
J Subst Use Addict Treat; 2024 Jun; 161():209248. PubMed ID: 38081540
[TBL] [Abstract][Full Text] [Related]
3. Massachusetts Justice Community Opioid Innovation Network (MassJCOIN).
Evans EA; Stopka TJ; Pivovarova E; Murphy SM; Taxman FS; Ferguson WJ; Bernson D; Santelices C; McCollister KE; Hoskinson R; Lincoln T; Friedmann PD;
J Subst Abuse Treat; 2021 Sep; 128():108275. PubMed ID: 33483222
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of extended-release injectable naltrexone among incarcerated persons with opioid use disorder before release from prison versus after release.
Jalali A; Jeng PJ; Polsky D; Poole S; Ku YC; Woody GE; Murphy SM
J Subst Abuse Treat; 2022 Oct; 141():108835. PubMed ID: 35933942
[TBL] [Abstract][Full Text] [Related]
5. Association of Receipt of Opioid Use Disorder-Related Telehealth Services and Medications for Opioid Use Disorder With Fatal Drug Overdoses Among Medicare Beneficiaries Before and During the COVID-19 Pandemic.
Jones CM; Shoff C; Blanco C; Losby JL; Ling SM; Compton WM
JAMA Psychiatry; 2023 May; 80(5):508-514. PubMed ID: 36988913
[TBL] [Abstract][Full Text] [Related]
6. Optimizing the impact of medications for opioid use disorder at release from prison and jail settings: A microsimulation modeling study.
Macmadu A; Adams JW; Bessey SE; Brinkley-Rubinstein L; Martin RA; Clarke JG; Green TC; Rich JD; Marshall BDL
Int J Drug Policy; 2021 May; 91():102841. PubMed ID: 32712165
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of Treatments for Opioid Use Disorder.
Fairley M; Humphreys K; Joyce VR; Bounthavong M; Trafton J; Combs A; Oliva EM; Goldhaber-Fiebert JD; Asch SM; Brandeau ML; Owens DK
JAMA Psychiatry; 2021 Jul; 78(7):767-777. PubMed ID: 33787832
[TBL] [Abstract][Full Text] [Related]
8. Receipt of Telehealth Services, Receipt and Retention of Medications for Opioid Use Disorder, and Medically Treated Overdose Among Medicare Beneficiaries Before and During the COVID-19 Pandemic.
Jones CM; Shoff C; Hodges K; Blanco C; Losby JL; Ling SM; Compton WM
JAMA Psychiatry; 2022 Oct; 79(10):981-992. PubMed ID: 36044198
[TBL] [Abstract][Full Text] [Related]
9. Population-level impact of initiating pharmacotherapy and linking to care people with opioid use disorder at inpatient medically managed withdrawal programs: an effectiveness and cost-effectiveness analysis.
Savinkina A; Madushani RWMA; Eftekhari Yazdi G; Wang J; Barocas JA; Morgan JR; Assoumou SA; Walley AY; Linas BP; Murphy SM
Addiction; 2022 Sep; 117(9):2450-2461. PubMed ID: 35315162
[TBL] [Abstract][Full Text] [Related]
10. Medication for Opioid Use Disorder After Nonfatal Opioid Overdose and Association With Mortality: A Cohort Study.
Larochelle MR; Bernson D; Land T; Stopka TJ; Wang N; Xuan Z; Bagley SM; Liebschutz JM; Walley AY
Ann Intern Med; 2018 Aug; 169(3):137-145. PubMed ID: 29913516
[TBL] [Abstract][Full Text] [Related]
11. Comparative Effectiveness Associated With Buprenorphine and Naltrexone in Opioid Use Disorder and Cooccurring Polysubstance Use.
Xu KY; Mintz CM; Presnall N; Bierut LJ; Grucza RA
JAMA Netw Open; 2022 May; 5(5):e2211363. PubMed ID: 35536575
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of full and partial opioid agonists for opioid use disorder in outpatient settings: United States healthcare sector perspective.
Choi SA; Yan CH; Gastala NM; Touchette DR; Stranges PM
J Subst Use Addict Treat; 2024 May; 160():209237. PubMed ID: 38061629
[TBL] [Abstract][Full Text] [Related]
13. Modeling the cost-effectiveness and impact on fatal overdose and initiation of buprenorphine-naloxone treatment at syringe service programs.
Adams JW; Savinkina A; Fox A; Behrends CN; Madushani RWMA; Wang J; Chatterjee A; Walley AY; Barocas JA; Linas BP
Addiction; 2022 Oct; 117(10):2635-2648. PubMed ID: 35315148
[TBL] [Abstract][Full Text] [Related]
14. Impact of jail-based methadone or buprenorphine treatment on non-fatal opioid overdose after incarceration.
Cherian T; Lim S; Katyal M; Goldfeld KS; McDonald R; Wiewel E; Khan M; Krawczyk N; Braunstein S; Murphy SM; Jalali A; Jeng PJ; Rosner Z; MacDonald R; Lee JD
Drug Alcohol Depend; 2024 Jun; 259():111274. PubMed ID: 38643529
[TBL] [Abstract][Full Text] [Related]
15. The impact of the implementation of medication for opioid use disorder and COVID-19 in a statewide correctional system on treatment engagement, postrelease continuation of care, and overdose.
Klemperer EM; Wreschnig L; Crocker A; King-Mohr J; Ramniceanu A; Brooklyn JR; Peck KR; Rawson RA; Evans EA
J Subst Use Addict Treat; 2023 Sep; 152():209103. PubMed ID: 37311520
[TBL] [Abstract][Full Text] [Related]
16. Prison Buprenorphine Implementation and Postrelease Opioid Use Disorder Outcomes.
Bovell-Ammon BJ; Yan S; Dunn D; Evans EA; Friedmann PD; Walley AY; LaRochelle MR
JAMA Netw Open; 2024 Mar; 7(3):e242732. PubMed ID: 38497959
[TBL] [Abstract][Full Text] [Related]
17. Cardiac and mortality outcome differences between methadone, buprenorphine and naltrexone prescriptions in patients with an opioid use disorder.
Wang L; Volkow ND; Berger NA; Davis PB; Kaelber DC; Xu R
J Clin Psychol; 2023 Dec; 79(12):2869-2883. PubMed ID: 37584532
[TBL] [Abstract][Full Text] [Related]
18. An ethical analysis of medication treatment for opioid use disorder (MOUD) for persons who are incarcerated.
Brezel ER; Powell T; Fox AD
Subst Abus; 2020; 41(2):150-154. PubMed ID: 31800376
[TBL] [Abstract][Full Text] [Related]
19. Emergency department utilization by individuals with opioid use disorder who were recently incarcerated.
Will J; Abare M; Olson M; Chyorny A; Wilhelm-Leen E
J Subst Abuse Treat; 2022 Oct; 141():108838. PubMed ID: 35868162
[TBL] [Abstract][Full Text] [Related]
20. Correlates and Patterns in Use of Medications to Treat Opioid Use Disorder in Jail.
Bailey A; Senthilkumar R; Evans EA
J Addict Med; 2023 Sep-Oct 01; 17(5):568-573. PubMed ID: 37788611
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
